S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61

89bio Stock Forecast, Price & News

-0.15 (-4.14%)
(As of 06/24/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
1.26 million shs
Average Volume
235,072 shs
Market Capitalization
$70.62 million
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive ETNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 89bio and its competitors with MarketBeat's FREE daily newsletter.

ETNB Stock Forecast (MarketRank)

Overall MarketRank

2.25 out of 5 stars

Medical Sector

339th out of 1,411 stocks

Pharmaceutical Preparations Industry

144th out of 672 stocks

Analyst Opinion: 3.6Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
89bio logo

About 89bio (NASDAQ:ETNB)

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

ETNB Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
$-90.12 million
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$6.21 per share


Free Float
Market Cap
$70.62 million
Not Optionable

89bio Frequently Asked Questions

Should I buy or sell 89bio stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for 89bio in the last twelve months. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" 89bio stock.
View analyst ratings for 89bio
or view top-rated stocks.

What is 89bio's stock price forecast for 2022?

7 brokers have issued 1 year target prices for 89bio's stock. Their ETNB stock forecasts range from $12.00 to $60.00. On average, they expect 89bio's share price to reach $34.88 in the next twelve months. This suggests a possible upside of 905.0% from the stock's current price.
View analysts' price targets for 89bio
or view top-rated stocks among Wall Street analysts.

How has 89bio's stock price performed in 2022?

89bio's stock was trading at $13.07 at the beginning of 2022. Since then, ETNB shares have decreased by 73.5% and is now trading at $3.47.
View the best growth stocks for 2022 here

When is 89bio's next earnings date?

89bio is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for 89bio

How were 89bio's earnings last quarter?

89bio, Inc. (NASDAQ:ETNB) released its quarterly earnings results on Wednesday, May, 11th. The company reported ($1.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.38) by $0.12.
View 89bio's earnings history

Who are 89bio's key executives?

89bio's management team includes the following people:
  • Mr. Rohan Palekar, CEO & Director (Age 56, Pay $829.41k) (LinkedIn Profile)
  • Mr. Quoc Le-Nguyen, Chief Technical Operations Officer & Head of Quality (Age 54, Pay $571.12k)
  • Dr. Harry Mansbach M.D., Chief Medical Officer (Age 57, Pay $603.22k)
  • Mr. Ryan Stephen Martins, Chief Financial Officer (Age 44)
  • Mr. Ram Waisbourd, COO & Chief Bus. Officer (Age 55) (LinkedIn Profile)
  • Mr. Shiva K. Natarajan, Sr. VP of Fin. & Principal Accounting Officer (Age 56)
  • Ms. Melissa Abel, Sr. VP of Commercial Strategy & Communications
  • Ms. Amanda Hill, VP of People & Culture
  • Ms. Yun Bai, VP & Head of CMC
  • Mr. Paul Shin, Sr. VP of R&D Operations

What other stocks do shareholders of 89bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 89bio investors own include Cisco Systems (CSCO), Pfizer (PFE), CVS Health (CVS), (HON), Raytheon Technologies (RTX), Alibaba Group (BABA), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ) and Thermo Fisher Scientific (TMO).

When did 89bio IPO?

(ETNB) raised $70 million in an initial public offering on the week of November 11th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.

What is 89bio's stock symbol?

89bio trades on the NASDAQ under the ticker symbol "ETNB."

Who are 89bio's major shareholders?

89bio's stock is owned by a number of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (8.76%), BlackRock Inc. (4.53%), Bank of America Corp DE (2.06%), Vanguard Group Inc. (1.99%), Pekin Hardy Strauss Inc. (1.77%) and Renaissance Technologies LLC (1.29%). Company insiders that own 89bio stock include Gregory Grunberg, Longitude Capital Partners Iii, Ollin B Sykes, Orbimed Advisors Llc, Ra Capital Management, LP, Ram Waisbourd, Rohan Palekar and Ryan Martins.
View institutional ownership trends for 89bio

Which major investors are selling 89bio stock?

ETNB stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Vanguard Group Inc., Charles Schwab Investment Management Inc., and Northern Trust Corp. Company insiders that have sold 89bio company stock in the last two years include Gregory Grunberg, Orbimed Advisors Llc, Ram Waisbourd, and Ryan Martins.
View insider buying and selling activity for 89bio
or view top insider-selling stocks.

Which major investors are buying 89bio stock?

ETNB stock was acquired by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Renaissance Technologies LLC, Pekin Hardy Strauss Inc., BlackRock Inc., JPMorgan Chase & Co., Goldman Sachs Group Inc., GSA Capital Partners LLP, and XTX Topco Ltd. Company insiders that have bought 89bio stock in the last two years include Longitude Capital Partners Iii, Ollin B Sykes, Ra Capital Management, LP, and Rohan Palekar.
View insider buying and selling activity for 89bio
or or view top insider-buying stocks.

How do I buy shares of 89bio?

Shares of ETNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 89bio's stock price today?

One share of ETNB stock can currently be purchased for approximately $3.47.

How much money does 89bio make?

89bio (NASDAQ:ETNB) has a market capitalization of $70.62 million. The company earns $-90.12 million in net income (profit) each year or ($5.00) on an earnings per share basis.

How many employees does 89bio have?

89bio employs 41 workers across the globe.

How can I contact 89bio?

89bio's mailing address is 142 SANSOME STREET SECOND FLOOR, SAN FRANCISCO CA, 94104. The official website for 89bio is www.89bio.com. The company can be reached via phone at 415-500-4614 or via email at [email protected].

This page (NASDAQ:ETNB) was last updated on 6/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.